Abstract--Autophagy, a process of self-digestion of the cytoplasm and organelles through which cellular components are recycled for reuse or energy production, is an evolutionarily conserved response to metabolic stress found in eukaryotes from yeast to mammals. It is noteworthy that autophagy is also associated with various pathophysiologic conditions in which this cellular process plays either a cytoprotective or cytopathic role in response to a variety of stresses such as metabolic, inflammatory, neurodegenerative, and therapeutic stress. It is now generally believed that modulating the activity of autophagy through targeting specific regulatory molecules in the autophagy machinery may impact disease processes, thus autophagy may represent a new pharmacologic target for drug development and therapeutic intervention of various human disorders. Induction or inhibition of autophagy using small molecule compounds has shown promise in the treatment of diseases such as cancer. Depending on context, induction or suppression of autophagy may exert therapeutic effects via promoting either cell survival or death, two major events targeted by therapies for various disorders. A better understanding of the biology of autophagy and the pharmacology of autophagy modulators has the potential for facilitating the development of autophagy-based therapeutic interventions for several human diseases.
I. Introduction: Autophagy as a New
Therapeutic Target Autophagy, literally meaning "self-eating" in Greek and discovered more than half a century ago, is an evolutionarily conserved and genetically controlled cellular response to nutrient deprivation that is found in yeast, plants, worms, flies, mice, and humans. This cellular catabolic process is characterized by formation of double-membrane vesicles ("autophagosomes") in the cytosol that first engulf organelles and cytoplasm and then fuse with the lysosomes to form the autolysosomes in which the contents are degraded and recycled for synthesis of ATP and various macromolecules such as proteins (Levine and Klionsky, 2004) . In the absence of stress, basal autophagy may function as a housekeeper by degrading intracellular damaged proteins and organelles (Levine and Klionsky, 2004) .
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Autophagy, Diseases, and Pharmacology consumption and cannibalistic cell death. Under certain circumstances, autophagy is also considered a form of nonapoptotic cell death termed "type II programmed cell death" or autophagic cell death (Bergmann, 2007) . Whereas autophagic cell death rests largely on circumstantial evidence, autophagic cell survival is supported by direct evolutionary, genetic, and biochemical studies. Autophagy is induced by a broad range of intracellular or extracellular stresses to degrade protein aggregates, oxidized lipids, damaged organelles, and even intracellular pathogens, thus having a variety of physiologic and pathophysiologic roles such as development and differentiation, life-span extension, elimination of microorganisms, and antigen presentation (Ravikumar et al., 2010) .
In recent years, accumulating evidence has pointed to the importance and functional role of autophagy in various human diseases. For instance, it is becoming increasingly clear that altered autophagy activity is associated with tumor formation and progression as well as with altered response to cancer therapy Janku et al., 2011) . Numerous studies indicate that autophagy is activated in tumor cells exposed to certain types of chemotherapy and targeted therapy Janku et al., 2011) . Defects in autophagy are found to be involved in premature aging (Rajawat et al., 2009) , neurodegenerative diseases, and cardiovascular disorders Rubinsztein et al., 2012) . In addition, it appears that defects in autophagy can lead to an increased susceptibility to infection and can be associated with autoimmune and inflammatory diseases (Deretic and Levine, 2009; Deretic, 2010; Levine et al., 2011) .
Recently, substantial progress has been made in identifying genes, proteins, signaling pathways, and related molecular mechanisms that are involved in autophagy regulation. This has permitted the manipulation of autophagy by inhibiting or activating autophagy-related genes and proteins using genetic and/or pharmacologic approaches. Notably, an increasing number of autophagy-related genes, proteins, and pathways have been found to be aberrant or altered in human diseases, offering novel targets for therapeutic intervention. Indeed, modulating autophagic processes has already shown promise in the treatment of certain human diseases, and autophagy has been emerging as a promising and attractive new target of great interest to the pharmaceutical industry. Recently, great efforts have been made in developing autophagy-based pharmacotherapy for various human health problems. This review will provide an overview of our current understanding of the biology of autophagy and the roles that autophagy plays in the pathophysiology of various human disorders. Our goal is to show how autophagy modulators may lead to a new generation of therapeutic agents for the treatment of various human diseases.
II. Cellular and Molecular Biology of Autophagy

A. Types of Autophagy and the Basic Process
Three types of autophagy have been defined based on the process and mechanisms by which the target substrates are delivered to lysosomes for degradation: macroautophagy (Fig. 1A) , chaperone-mediated autophagy (CMA) (Fig. 1B) , and microautophagy (Fig. 1C) .
Macroautophagy (hereafter referred to as autophagy) involves the sequestration of intracellular components (such as proteins and organelles) into newly formed double-membrane vesicles termed autophagosomes, which subsequently fuse with the lysosomes for degradation. Schematically, the process of autophagy can be characterized by three main operational steps (Weidberg et al., 2011) . The first is the formation of autophagosomes and sequestration of cytoplasmic material into vesicles. This process involves three stages as follows: 1) initiation, the formation of the phagophore; 2) nucleation, the engulfment of the cytoplasmic material by the phagophore; and 3) elongation/ enclosure, the phagophore membrane elongation and fusion of its edges to form the autophagosome. The second is the fusion of the autophagosome with the lysosome to form the autolysosome. The third is the degradation of the sequestered materials for recycling and energy production.
Macroautophagy is further classified into two types as follows: nonselective autophagy and cargo-specific autophagy, which includes mitophagy, pexophagy, ribophagy, and xenophagy (Youle and Narendra, 2011) . Mitophagy, which mediates the selective elimination of damaged or excessive mitochondria, plays an essential role in maintaining mitochondrial quantity. Removal of damaged mitochondria through autophagy requires two steps as follows: induction of general autophagy and priming of damaged mitochondria for selective autophagic recognition (Ding and Yin, 2012) .
During the process of CMA, cytosolic proteins are recognized by heat-shock cognate protein (HSC70), a 70-kDa chaperone that mediates the translocation of proteins to the surface of the lysosomes where substrates bind to the lysosomal-associated membrane protein type 2A (LAMP-2A), leading to protein internalization and degradation (Kaushik and Cuervo, 2012) . CMA selectively recognizes proteins containing a KFERQ motif at the C-terminal sequence. This particular pentapeptide consensus motif is the only binding region recognized specifically by HSC70 for protein delivery to the lysosomes and is necessary and sufficient for degradation of the substrates through CMA (Chiang et al., 1989; Dice, 1990) . CMA involves the following steps: 1) recognition of the KFERQ region of cytosolic proteins by HSC70; 2) binding of substrate proteins to the cytosolic tail of LAMP-2A; 3) LAMP-2A multimerization and substrates translocation inside the lysosomes; and 4) substrate degradation and LAMP-2A dissociation into monomers (Chiang et al., 1989; Arias and Cuervo, 2011) .
Microautophagy involves direct internalization of cytoplasmic materials into the lysosome. Cellular constituents are sequestrated into the lysosomal lumen for degradation through invagination of the lysosomal membrane, which subsequently pinches off to form small vesicles (Mortimore et al., 1988) .
B. Physiologic Role of Autophagy
Autophagy is evolutionarily conserved in eukaryotes from yeast to mammals and has miscellaneous physiologic roles, including adaptation to starvation, clearance of intracellular proteins and organelles, development and differentiation, life-span extension, elimination of micro-organisms, and antigen presentation. The basal level of autophagy is generally viewed as a cellular housekeeper that is crucial for quality control of the integrity of intracellular proteins. In metabolic or other types of stress, induction of autophagy is important for intracellular generation of amino acids and other nutrient molecules for cellular survival. Conversely, excessive autophagy can cause nonapoptotic programmed cell death.
1. Autophagy-Dependent Cellular Homeostasis. There are two known cellular mechanisms for protein degradation: the ubiquitin-proteasome system (UPS) and the autophagy-lysosome system. The UPS is the major pathway for degradation of short-lived proteins (Hershko and Ciechanover, 1998) , whereas the autophagy is mainly responsible for degradation of long-lived proteins and other cellular contents and is the mechanism by which the large structures such as organelles and protein aggregates are degraded (Rabinowitz and White, 2010) . Under normal conditions, low level, constitutive autophagy participates in maintaining cellular homeostasis by degrading and recycling unnecessary or excessive cellular components, eliminating abnormal, aged, or potentially harmful molecules and organelles, and removing intracellular pathogens (Levine, 2005) .
Impaired autophagy may result in accumulation of abnormal and misfolded protein aggregates. In neural cells and hepatocytes from mice with knockout of the autophagy gene Atg5, abnormal intracellular proteins Macroautophagy begins with engulfment of the cytoplasmic materials by the phagophore, which sequesters the materials into a double-membrane vesicle (i.e., autophagosome). The autophagosome fuses with a lysosome to form an autolysosome, and then the cytoplasmic materials are degraded by the lysosome. The initiation step of autophagosome formation requires the ULK1-Atg13-FIP200 complex and Beclin1-class III PI3K complexes. Two conjugation systems, Atg12-Atg5-Atg16 and Atg8-PE, are essential for the elongation and enclosure step of the autophagosome formation. Lipid conjugation leads to the conversion of the soluble form of LC3-I to the autophagic vesicle-associated form LC3-II, which is commonly used as a marker of autophagy. mTOR plays a critical role in regulating autophagy: under nutrientrich conditions, mTOR is activated and inhibits autophagy through repression of ULK1 activity (the mammalian homologs of ATG1). Growth factors such as insulin or insulin-like growth factor can activate the class I PI3K-Akt/PKB pathway, which phosphorylates tuberous sclerosis complex (TSC2) and prevents the formation of an TSC1/2 protein complex, resulting in activation of mTOR. (B) Chaperone-mediated autophagy. During chaperonemediated autophagy, the cytosolic proteins bind to the LAMP-2A receptor in an Hsc70 chaperone-dependent manner for translocation to the lysosomes, leading to their internalization and degradation. (C) Microautophagy. Microautophagy involves the direct sequestration of the cellular components by the lysosome through invagination of the lysosomal membranes.
Autophagy, Diseases, and Pharmacology accumulate and form aggregates and inclusions (Hara et al., 2006) . Likewise, mice with deficiency of the autophagy gene Atg7 accumulate intracellular ubiquitinated aggregates in the cytoplasm of hepatocytes and neurons (Komatsu et al., 2005 (Komatsu et al., , 2006 . These observations indicate that continuous clearance of the diffused cytosolic proteins through basal autophagy is essential for homeostasis and that autophagy plays a key role in quality control of the cellular components by removing abnormal and potentially harmful proteins.
Autophagy is also involved in monitoring the quality of important organelles such as the mitochondria. Mice with Atg7 deficiency show multiple cellular abnormalities, including the appearance of concentric membranous structure and deformed mitochondria (Komatsu et al., 2005) . The hearts of the Atg5-deficient mice display disorganized sarcomere structure, and mitochondrial misalignment and aggregation (Nakai et al., 2007) . Mitochondria with loss of integrity can be selectively removed by autophagy, a process termed "mitophagy" (Marino and Lopez-Otin, 2004) . In rat hepatocytes, nutrient deprivation initiates mitochondrial depolarization and subsequent sequestration of the mitochondria into autophagosomes (Elmore et al., 2001) . Although selective degradation of the mitochondria by mitophagy is vital for cellular homeostasis, the molecular mechanisms of mitophagy remain incompletely understood. So far, Atg11, Atg32, and Atg8 have been identified as critical regulators of mitophagy (Kanki and Klionsky, 2008; Kanki et al., 2009; Okamoto et al., 2009) . In mammals, autophagic degradation of depolarized mitochondria is initiated by the Pink1-dependent mitochondrial translocation of Parkin, followed by ubiquitination of mitochondrial proteins and recruitment of p62 to direct the mitochondria to autophagosomes (Geisler et al., 2010) . Recently, Bif-1, a member of the membrane curvature-driving endophilin family of proteins, was found to be required for autophagy-dependent clearance of damaged mitochondria (Takahashi et al., 2013) .
Autophagy also plays critical roles in development and differentiation. For instance, autophagy is vital for the preimplantation development period after oocyte fertilization, and for the early postnatal period during neonatal starvation (Mizushima and Levine, 2010) . Altered autophagy can affect embryogenesis, including midembryonic development. Atg5, a key autophagyregulatory gene, is required for the engulfment of apoptotic cells during the morphogenesis of specific organs in late embryonic development . Autophagy enables cells to undergo structural remodeling and contributes to cellular differentiation during erythropoiesis, lymphopoiesis, and adipogenesis (Rubinsztein et al., 2012) .
2. Autophagy-Dependent Cellular Survival. With different types of stress (e.g., such as nutrient deprivation, growth factor depletion, hypoxia, cytotoxic insult), activation of autophagy can generate intracellular metabolic substrates for maintenance of cellular energy demands. The amino acids and fatty acids generated from autophagic degradation of membrane proteins and lipids may provide essential nutrients for survival of the organism subjected to a variety of stresses (Rabinowitz and White, 2010) . One of the typical triggers of autophagy is nutrient starvation, which can induce autophagy in yeast, plant cells, mammalian cells, and whole animals to provide nutrients and energy to support survival. Autophagy-defective cells fail to maintain physiologic levels of amino acid; when subjected to starvation, both intracellular and extracellular concentrations of amino acids decrease in autophagy-deficient cells and animals to a greater extent than in wild-type littermates. In yeast cells harboring the Atg7 mutant, the total pool of intracellular amino acids was reduced, but the wild-type cells maintained amino acid concentrations compatible with life (Onodera and Ohsumi, 2005) . Atg5-deficient neonatal mice had decreased amino acid concentrations in both plasma and tissues (Kuma et al., 2004) . Atg7 2/2 mice not only had a lower level of amino acids but also died earlier after birth as compared with the wild-type animals (Komatsu et al., 2005) . The amino acids and fatty acids generated through autophagy can be used by the tricarboxylic acid (TCA) cycle to maintain ATP production in the mitochondria . In addition, those amino acids can be used for protein synthesis, as the impaired protein synthesis in the Atg7 mutant yeast cells was much more severe than in the wild-type cells during starvation (Onodera and Ohsumi, 2005) .
In yeast, autophagy-defective cells are susceptible to starvation-induced damage. Upon nitrogen starvation, plants with mutant autophagy genes show defects in development, including accelerated senescence and enhanced chlorosis (Hanaoka et al., 2002; Yoshimoto et al., 2004) . The postnatal survival time of the starved mice deficient for Atg5 was less than 12 hours but was prolonged by forced milk feeding, indicating the importance of the nutrient supply derived from neonatal autophagy in supporting survival of life (Kuma et al., 2004) . Similarly, mice deficient in Atg7 suffered from severe nutrient and energy insufficiency shortly after birth (Komatsu et al., 2005) .
Equally important, cellular autophagy also plays a cytoprotective or prosurvival role under stressful conditions such as growth factor deprivation (Lum et al., 2005) and treatment with chemotherapy or anti-infective agents (Maiuri et al., 2007b) . These studies provide compelling evidence that the nutrients generated through autophagy are important for survival during stress, supporting the notion that autophagy is a selfprotective mechanism of living organisms under various stressful conditions.
3. Autophagic Cell Death. Above and beyond the studies of the role of autophagy in cellular survival, 1166 there has also been extensive interest in autophagyassociated cell death, referred to as type II programmed cell death. As early as the 1960s, autophagic vacuoles containing organelles such as mitochondria were first observed in dying animal cells (Ashford and Porter, 1962) . This area of investigation is confounded by the possibility that the appearance of autophagy in dead or dying cells is an unsuccessful cellular attempt at survival. As mentioned previously, cells or organisms deficient in autophagy may die more rapidly rather than more slowly. Subsequent studies found that autophagic cell death often occurs when groups of cells or entire tissues die during development, and these dying cells contain "autophagic vacuoles" in the cytoplasm (Baehrecke, 2002) . More recently, autophagic cell death was observed in tumor cells treated with chemopreventive or chemotherapeutic agents such as resveratrol (Opipari et al., 2004) , arsenic trioxide (Kanzawa et al., 2003) , and tamoxifen (Bursch et al., 1996) . Support for the role of autophagy in cell death was provided via the use of autophagy inhibitors, which can rescue cell death resulting from autophagy. For example, 3-methyladenine (3-MA), an inhibitor of class III phosphatidylinositol-3 kinase (PI3K) that blocks the initial step of autophagy, has been reported to suppress autophagy and inhibit cell death in several cell lines subjected to various drug treatments including tamoxifen (Bursch et al., 1996) , tumor necrosis factor a (TNF-a) and bacterial toxins (Bursch, 2001) . Studies also showed that knockdown of some key autophagy genes can reduce cell death. The small molecule compound STF-62247 [N-(3-methylphenyl)-4-pyridin-4-yl-1,3-thiazol-2-amine] promotes cell death in renal cell carcinoma both in vitro and in vivo through inducing autophagy, and inhibition of autophagy by the small-interfering RNA (siRNA) against Atg7 or Atg9 decreases the sensitivity of the tumor cells to STF-62247 (Turcotte et al., 2008) . Nonapoptotic cell death induced by z-VAD, a caspase inhibitor, was decreased when cells were cotreated either with the autophagy inhibitors 3-MA and wortmannin or subjected to the RNAi-mediated knockdown of Atg7 and Beclin1; this suggests that inhibition of caspase arrests apoptosis but activates autophagic cell death (Yu et al., 2004) . In Bax 2/2 Bak 2/2 murine embryonic fibroblasts (MEFs) treated with etoposide (a topoisomerase II poison) or staurosporine (a prototypical ATP-competitive kinase inhibitor), two inducers of apoptosis, nonapoptotic cell death accompanied by autophagic vacuolization was reduced when Atg5 or Beclin1 was knocked down (Shimizu et al., 2004) . Autophagic cell death can be revealed when apoptosis is blocked (Maiuri et al., 2007b) . Additionally, excessive autophagy can cause cannibalistic cell death (Bergmann, 2007) . Although there are numerous scenarios in which autophagyassociated cell death may occur, the importance and significance of autophagy in promoting cell death and its relationship with apoptotic cell death are still the subject of intensive investigation .
As there are a number of examples of cell death associated with autophagy, the question of how important the autophagic process is in cell death was recently reviewed by Kroemer and Levine (2008) . Certain studies suggest that inhibition of autophagy may result in either delayed or partial inhibition rather than prevention of cell death. Because inhibition of autophagy by pharmacologic agents or genetic manipulations also may have some off-target effects on cellular functions, the question of whether cell death can truly occur due to autophagy alone remains to be clarified.
C. Regulation of Autophagy and the Signaling Pathways
The past decade has seen remarkable elucidation of many molecular mechanisms and pathways that are critically involved in the regulation of autophagy. We will now review the studies that have facilitated our understanding of the implications of autophagy in human health and disease.
1. Molecular Regulation of Autophagy. Studies of the genes and gene products involved in the regulation of autophagy have advanced our knowledge of the molecular basis of this cellular process. To date, more than 30 autophagy-related genes (Atg) have been identified in yeast, most of which function in the formation of autophagosome (Yang and Klionsky, 2010) . All the Atg proteins found in yeast have mammalian homologs, suggesting that the molecular machineries of autophagy operating in yeast are also used in other eukaryotic cells.
Beclin1, the mammalian homolog of yeast autophagy gene Atg6, was the first identified autophagy gene in mammalian cells (Li et al., 2012) . The initiation step of autophagosome formation requires the Beclin1-class III PI3K complex, which contains Beclin1, Vps34 (class III PI3K), and p150 (Simonsen and Tooze, 2009) . Recently, Beclin1 was found to interact with additional proteins, including Atg14, UV radiation resistanceassociated gene (UVRAG) product (Liang et al., 2006; Itakura et al., 2008; Li et al., 2012) , and activating molecule in Beclin1-regulated autophagy protein 1 (AMBRA1) (Fimia et al., 2007) . All these proteins are present in the Vps34 complex and act as inducers of autophagy. The Rubicon protein is a negative regulator of autophagy because when it binds to Beclin1 it reduces the activity of Vps34 and impairs the formation of autophagosome (Zhong et al., 2009 ). Atg1 plays a key role in the early stage of autophagy by forming a complex with Atg13 and Atg17, both of which enhance Atg1 kinase activity and promote autophagosome generation (Ganley et al., 2009; Hara and Mizushima, 2009; Hosokawa et al., 2009 ). The components Autophagy, Diseases, and Pharmacology of this complex are mostly conserved from yeast to human; the serine/threonine kinase ULK1, mATG13, and FIP200 are the mammalian functional homologs of the yeast Atg1, Atg13, and Atg17, respectively. Atg13 promotes the formation of the Atg1-Atg1 self-interaction complex, which is correlated with the kinase activity of Atg1 and the amount of autophagy (Yeh et al., 2011) . Atg8 was recently identified as a regulator of Atg1, which directly binds to Atg1 and enhances its activity in autophagy (Kraft et al., 2012) .
Two ubiquitin-like conjugation systems, the Atg12-Atg5-Atg16 complex and the Atg8-phosphatidylethanolamine complex (PE), participate in the elongation/enclosure step that is critical for autophagosome formation. These conjugation systems are conserved in various eukaryotes. In the first ubiquitin-like system, Atg12 is conjugated to Atg5 through Atg7 and Atg10, an E1-like ubiquitin-activating enzyme and an E2-like ubiquitinconjugating enzyme, respectively (Mizushima et al., 1998) . The E1-like Atg7 binds to the C-terminal glycine of Atg12 through its active cysteine site to form an intermediate complex via a thioester bond. Subsequently, Atg12 is activated by ATP hydrolysis and transferred to the E2-like Atg10. The C-terminal glycine of Atg12 then covalently binds to an internal lysine residue of Atg5 to form the final conjugate. The Atg5-Atg12 conjugates interact noncovalently with Atg16 (Mizushima et al., 1999) . The Atg12-Atg5-Atg16 complex then associates with phagophores and dissociates when formation of autophagosomes is completed (Yorimitsu and Klionsky, 2005) .
The second conjugation system involves the cleavage and lipidation of Atg8 (Ichimura et al., 2000) . Atg8 is cleaved near the C-terminal glycine residue by the cysteine protease Atg4, subsequently is activated by the E1-like Atg7, is transferred to the E2-like Atg3, and eventually is conjugated to the lipid PE. Atg8-PE can be detected on both of the intermediate vesicle and the completed autophagosome. This complex is transported to the lysosome/vacuole and degraded along with the cargo. There are at least three Atg8 homologs in mammalian cells: GATE-16 (Golgi-associated ATPase enhancer of 16 kDa), GABARAP (g-aminobutyric acid type A receptor-associated protein), and MAP1LC3 (microtubule-associated protein 1 light chain 3). All these proteins are modified with lipid in the same manner as occurs in yeast, and all localize to the autophagosome (Kabeya et al., 2004) . In mammalian cells, light chain 3 (LC3) is cleaved by Atg4 to form the cytosolic soluble LC3-I, which can be further cleaved and converted to a membrane-associated form LC3-II through conjugating with the lipid PE (Kabeya et al., 2000) .
LC3-II, the cleaved product of LC3-I, is inserted within the inner and outer membrane of the vesicles during autophagosome formation. LC3 has been intensely characterized and, like yeast Atg8, is commonly used as a marker for the mammalian autophagosome. In addition, LC3-II remains on the mature autophagosomes until fusion with lysosomes is completed. Thus, the fusion of the autophagosome with lysosomes can be assessed by colabeling LC3 and LAMP1, a lysosomeassociated membrane protein (Weidberg et al., 2011) . p62/SQSTM1 (sequestosome 1), an ubiquitin-binding scaffold protein, binds directly to LC3 via a specific sequence motif and is degraded by the autophagic process. p62/SQSTM1 can also link ubiquitinated proteins to the autophagic machinery to enable their degradation in the lysosome (Pankiv et al., 2007) . When autophagy is suppressed, p62/SQSTM1 markedly accumulates. In contrast, the amount of p62/SQSTM1 decreases when autophagy is activated, thus p62 is often used as a marker for autophagic flux. Another commonly used method for measurement of autophagy flux is to monitor the conversion of LC3-I to LC3-II in the presence of lysosomal cysteine and/or aspartic proteinase inhibitors such as E-64 day and pepstatin A .
2. Signaling Pathways Regulating Autophagy. a. Mammalian target of rapamycin. Mammalian target of rapamycin (mTOR), a PI3K-related serine/ threonine protein kinase, is a key regulator of cell growth and proliferation. mTOR regulates various cellular functions such as energy metabolism, translation initiation, and cytoskeletal organization (Schmelzle and Hall, 2000) . Recently, it was found that the mTOR signaling pathway also may regulate autophagy (Fig. 2) . When activated by nutrients, growth factors, or hormones such as insulin, mTOR inhibits autophagy. mTOR is present in two structurally and functionally distinct protein complexes known as mTORC1 and mTORC2. mTORC1 consists of mTOR, mLST8 (mammalian lethal with SEC13 protein 8), Raptor (regulatoryassociated protein of mTOR), PRAS40 (proline-rich Akt substrate of 40 kDa), and DEPTOR (DEP domain containing mTOR-interacting protein), and is rapamycin sensitive. mTORC2 contains mTOR, mLST8, Rictor (rapamycin-insensitive companion of mTORC2), mSin1 (mammalian stress-activated MAP kinase-interacting protein 1), and Protor-1/Protor-2 (protein observed with Rictor-1/protein observed with Rictor-2) (Sabatini, 2006; Pearce et al., 2011) . mTORC1 is downstream of PI3K and is activated in response to mitogenic stimuli or nutrient availability (Hay and Sonenberg, 2004) . Growth factors such as insulin and insulin-like growth factor bind to their receptor tyrosine kinases, leading to autophosphorylation of these receptors, with subsequent phosphorylation of insulin receptor substrates (IRS). Phosphorylated insulin receptor substrates further recruit and activate the class I PI3K-Akt/PKB, which then phosphorylates tuberous sclerosis complex (TSC2) and prevents the formation and ability of TSC1/ 2 to act as a GTPase-activating protein for Rheb. Rheb activates mTOR1 when bound to GTP. Inhibition of TSC1-TSC2 by Akt phosphorylation allows Rheb-GTP to accumulate and activates mTOR (Proud, 2007) . Phosphatase and tensin homolog (PTEN), a phosphoinositide-3 phosphatase, antagonizes the signaling of the Akt/PKB pathway and is an activator of autophagy (Shaw and Cantley, 2006) . In general, activation of PI3K indirectly regulates AKT (protein kinase B), whose activity prevents tuberous-sclerosis complex-2 (TSC2)-mediated inhibition of Rheb.
Activation of mTOR has been known to be a negative regulator of autophagy. Although the precise mechanism by which mTORC1 controls autophagy and its direct target(s) remains unclear, mTORC1 is believed to act in two ways. First, mTORC1 inhibits the association between Atg1 and Atg13. Under nutrient-rich conditions, the activated mTORC1 induces the phosphorylation of Atg13 and prevents its association with Atg1. When subjected to nutrient deprivation or rapamycin treatment, Atg13 is rapidly dephosphorylated upon mTORC1 inactivation and shows a high affinity for Atg1. Formation of the Atg1-Atg13 complex results in activation of Atg1 and subsequent induction of autophagy (Kamada et al., 2000 (Kamada et al., , 2010 . The human homolog of Atg13 is also a direct substrate for mTOR (Jung et al., 2009) . Second, mTORC1 inactivates ULK1 by phosphorylating this protein. Inactivation of mTOR1 leads to dephosphorylation and activation of Ulk1 and consequently induces autophagy under conditions of starvation or rapamycin treatment (Kim et al., 2011a; . Our laboratory has been particularly interested in elongation factor 2 kinase (eEF2K), an enzyme that catalyzes the phosphorylation of eEF-2, a 100-kDa protein involved in the translocation step in peptide-chain elongation. Phosphorylation of eEF-2 on Thr56 decreases its affinity for the ribosome, thereby terminating elongation. As shown in Fig. 2 , this kinase is exquisitely controlled by mTOR and AMP-activated protein kinase (AMPK) (Horman et al., 2002; ). When energy is abundant, eEF2K is inhibited by the activity of mTOR and protein elongation occurs; in contrast, when energy is deficient, the activity of mTOR is decreased, and eEF2K is activated, thereby inhibiting peptide elongation and conserving Autophagy, Diseases, and Pharmacology energy. Several lines of evidence suggest that there is a direct link between the activity of eEF2k and autophagy. For example, we found that eEFK can act as a positive regulator of autophagy under environmental or metabolic stresses, including nutrient deprivation (Wu et al., 2006) , growth factor inhibition , endoplasmic reticulum stress , and energy stress caused by the glycolytic inhibitor 2-deoxy-D-glucose (Wu et al., 2009) .
b. AMP-activated protein kinase. Activated protein kinase (AMPK), a serine/threonine protein kinase, is a chief sensor of cellular energy and regulates the metabolism of glucose and lipids in response to alterations in nutrient and intracellular ATP concentrations. AMPK is activated when the intracellular AMP/ATP ratio increases. AMPK can be phosphorylated on different sites by various kinases. Phosphorylation of AMPK on Thr172 within its catalytic a subunit is necessary for the activation of this kinase. Recent studies have identified liver kinase B1 (LKB1), the major upstream activating kinase of AMPK, Ca 2+ / calmodulin-dependent protein kinase kinase-b (CaMKKb), and transforming growth factor-b-activated kinase (TAK1) as major kinases that phosphorylate AMPK on Thr172 and cause activation of this kinase (Momcilovic et al., 2006; Carling et al., 2008) . AMPK also contains other phosphorylation sites in the a-subunit, including Thr258, Ser485, and Ser491, but these phosphorylation sites are not involved in activation of this kinase (Woods et al., 2003) . The native b 1 -subunit of AMPK is phosphorylated at three sites: Ser24/Ser25, Ser108, and Ser182 (Mitchelhill et al., 1997) . It is known that mutation of the Ser108 site leads to the inhibition of AMPK, whereas the mutations on Ser24/ Ser25 and Ser182 sites have no effect on the enzyme activity (Warden et al., 2001) .
AMPK also participates in the regulation of other cellular functions, including maintenance of mitochondrial homeostasis, cell polarity, and cell growth and proliferation (Hardie, 2011) . Studies also have revealed that AMPK is an important regulator of autophagy (Meley et al., 2006; Liang et al., 2007; Matsui et al., 2007; Herrero-Martin et al., 2009) . AMPK-mediated suppression of mTOR is controlled by TSC2 and Raptor, two substrates of AMPK. Activation of AMPK by energy deficiency directly phosphorylates TSC2 on T1227 and S1345 and enhances the functions of TSC2, leading to suppression of mTORC1, the key downstream target of TSC1/TSC2 (Inoki et al., 2003) . Alternatively, AMPK can regulate the mTOR signaling by directly phosphorylating the mTOR binding partner Raptor on two conserved serine residues, Ser722 and Ser792; these phosphorylations enhance 14-3-3 binding to Raptor, resulting in the inactivation of Raptor and mTORC1 (Gwinn et al., 2008) .
AMPK also has a more direct link with autophagy through its interaction with and phosphorylation of ULK1 (Fig. 2) . AMPK binds to the N-terminal proline/ serine (PS) rich domain of ULK1, and this interaction is required for the ULK1-mediated autophagy (HerreroMartin et al., 2009) . Furthermore, AMPK can associate with and directly phosphorylate ULK1 on several sites, and this modification is required for ULK1 activation in response to nutrient deprivation (Egan et al., 2011) . Mack et al. (2012) reported that AMPK can interact with and phosphorylate ULK1 at Ser555, Ser637, and Thr659, and that AMPK-dependent phosphorylation of ULK1 is important for ULK1 regulation of ATG9 localization, resulting in increased autophagy efficiency. Similarly, under glucose starvation, AMPK promotes autophagy by directly phosphorylating ULK1 on Ser317 and Ser777, thus activating ULK1 (Kim et al., 2011a) . By contrast, Shang and co-workers found that ULK1 undergoes dramatic dephosphorylation on Ser638 and Ser758 upon starvation, and the dephosphorylation of ULK1 leads to its dissociation from AMPK and becoming more active in autophagy induction .
c. Bcl-2 family proteins. Bcl-2 family proteins were initially identified and characterized as regulators of cell survival and death; more recently, it has been revealed that the proteins of this family control the autophagic process as well. The antiapoptotic Bcl-2 family members, including Bcl-2, Bcl-XL, Bcl-wl, and Mcl-1, also inhibit autophagy (Fig. 2) . Conversely, proapoptotic Bcl-2 homology 3 (BH3)-only proteins such as BNIP3L, Bad, Noxa, Puma, BimEL22, and Bik stimulate autophagy (Maiuri et al., 2009b) . For example, the antiapoptotic proteins can interact with Beclin1 through the BH3 receptor domain and the BH3 domain on Belcin1, thereby inhibiting Beclin1-dependent autophagy (Pattingre et al., 2005) . The Bcl-2-Beclin1 interaction is inhibited by nutrient deprivation, leading to release of Beclin1 and activation of autophagy. Other proteins with BH3 domains can competitively disrupt the association between Beclin-1 and Bcl-2/Bcl-XL and induce autophagy. Mitophagy induced by hypoxia occurs through a hypoxia inducible factor-1 (HIF-1)-dependent transcriptional activation of BNIP3L that disrupts the interaction between Bcl-2 and Beclin1 (Bellot et al., 2009) . It is now widely appreciated that Bcl-2 is not only an antiapoptotic but also an antiautophagic protein.
d. The tumor suppressor p53 protein. p53 is a transcription factor that transactivates proapoptotic and cell cycle-arresting genes and is frequently inactivated or mutated in cancer cells (Vousden and Lane, 2007) . It has been found that inactivation of p53 can trigger autophagy in vitro and in vivo (Tasdemir et al., 2008) . Tasdemir et al. (2008) found that introduction of wild-type p53 into p53 2/2 cells inhibited autophagy, whereas forced expression of a nucleus-restricted form of p53 failed to suppress autophagy in the same cells, suggesting that cytoplasmic p53 is responsible for the inhibition of autophagy. In addition, many different inducers of autophagy stimulate proteasome-mediated degradation of p53, and inhibition of p53 degradation can prevent the activation of autophagy (Tasdemir et al., 2008) .
By contrast, nuclear p53 stimulates autophagy in a transcription-dependent fashion through activating the expression of the autophagy-inducing genes such as damage-regulated autophagy modulator (DRAM) (Crighton et al., 2006) and sestrin (Maiuri et al., 2009a) . p53 also activates autophagy by inhibiting mTOR in an AMPK-dependent and TSC1/TSC2-dependent manner (Chen and Debnath, 2010) . In addition, sestrin 1 and sestrin 2, two p53 target genes, have been identified as a critical link between p53 activation and mTOR inhibition (Budanov and Karin, 2008) . Thus, p53 can modulate autophagy in dual ways, depending on its cellular localization; nuclear p53 activates autophagy through transcriptional regulation, whereas cytoplasmic p53 inhibits autophagy (Fig. 2) .
III. Relevance of Autophagy to Human Diseases
Depending on the context, autophagy can play either a cytoprotective or cytopathic role in different pathophysiologic processes. Not surprisingly, dysregulation of autophagy can contribute to the pathogenesis of various human diseases, including cancer, obesity, cardiac disease, neurodegeneration, aging, and infectious and inflammatory diseases (Shintani and Klionsky, 2004; Levine and Yuan, 2005; Levine and Kroemer, 2008; Rubinsztein et al., 2012; Liu et al., 2013) (Table 1) .
A. Cancer
The association between autophagy and cancer is complex, as the role of autophagy may differ in different stages of disease. At early stages of tumor development, autophagy may prevent genomic instability and suppress growth of precancerous cells, acting as a tumor suppressor (Gozuacik and Kimchi, 2004) . Later in the course of disease, autophagy may favor the ability of cancer cells to survive metabolic and therapeutic stresses and thereby promote tumor progression.
1. Autophagy Suppresses Tumor Initiation. It is generally accepted that autophagy has a tumor suppressor function and that defects in autophagy contribute to tumor development. Malignant or transformed cells often display lower basal autophagic activity than their normal counterparts. For example, autophagic activity was lower in primary hepatocellular tumor cells than in normal hepatocytes in rat liver carcinogenesis models (Kisen et al., 1993) .
The identification of the genes required for autophagy provides the opportunity to use genetic approaches to investigate the role of autophagy in cancer development. Accordingly, the suppressive effect of autophagy on tumorigenesis has been evaluated using different models that are deficient for specific autophagy factors (Table 1) . Mice with a systemic mosaic deletion of Atg5 or mice with a liver-specific Atg7 deficiency developed benign tumors in the liver, suggesting that autophagy is critical for suppression of spontaneous tumorigenesis in this model (Takamura et al., 2011) . Mice with heterozygous disruption of Beclin1 showed an increased frequency of spontaneous cancers (Qu et al., 2003; Yue et al., 2003) . Beclin1 protein is expressed at a high level in normal breast epithelial cells but has much lower expression in breast cancer cell lines such as MCF-7 . Ectopic expression of Beclin1 in MCF-7 cells activates autophagy, inhibits cellular proliferation and clonogenicity, and suppresses tumorigenesis in mouse xenograft models . A functional Beclin1 also inhibits proliferation of other tumor cell lines . Monoallelic deletion of Beclin1 was observed in specimens of human breast, ovarian, and prostate cancers (Aita et al., 1999; Shintani and Klionsky, 2004) .
Besides Beclin1, several other components of the autophagic machinery were found to possess tumor suppressor functions. For example, mice deficient in Atg4C showed an increased susceptibility to chemically induced fibrosarcomas (Marino et al., 2007) . UVRAG, a positive regulator of the Beclin1-class III PI3K complex, is monoallelically deleted at a high frequency in human colon cancers, and it suppresses the proliferation and tumorigenicity of human colon cancer cells (Liang et al., 2006) . Knockout of Bif-1, an inducer of autophagy that interacts with Beclin1 and activates the Beclin1-class III PI3K complex, enhances the development of spontaneous tumors in mice (Takahashi et al., 2007) . Thus, autophagy genes may serve, under certain circumstances, as tumor suppressors.
Not only do mutations of the autophagy gene promote tumorigenesis, but autophagy is also positively regulated by the tumor suppressor genes and negatively regulated by the oncogenic signaling pathways. The class I PI3K/Akt signaling pathway promotes cell growth; mutations in several proteins of this pathway are found in high incidence in the common human malignancies. When the Akt signaling pathway is activated, autophagy is often reduced. For instance, Wang et al. (2012) found that Beclin1, an essential autophagy-regulatory protein, is a target of Akt, and that the Akt-mediated phosphorylation of Beclin1 leads to suppression of autophagy and is associated with oncogenesis, providing evidence for the role of the Akt-mediated down-regulation of autophagy in the oncogenic process. Conversely, the tumor suppressor PTEN, which antagonizes the signaling of the PI3K/ Akt pathway, can activate autophagy (Arico et al., 2001) . Mutations in PTEN result in constitutive activation of the Akt signaling pathway, suppression of autophagy, and tumor formation. Other tumor suppressors such as TSC1, TSC2, p53, and LKB1 stimulate autophagy through their inhibitory effects on Autophagy, Diseases, and Pharmacology mTOR (Rubinsztein et al., 2012) . Therefore, not only do autophagy genes control the autophagic activity, but oncogenes and tumor suppressor genes can also modulate this cellular process through which tumor initiation and development are influenced. The mechanisms by which autophagy suppresses tumor initiation and development appear to include limiting the accumulation of damaged proteins and organelles such as mitochondria; preventing genomic instability and subsequent cellular transformation (Jin, 2006; Mathew et al., 2007) ; and limiting the inflammation caused by necrosis (Degenhardt et al., 2006) . As in the case of chronic infection and toxin exposure, defects in the autophagic disposal can cause chronic tissue damage and inflammation, which may contribute to cancer Amaravadi et al., 2011) . Also, autophagy can inhibit tumor growth by degrading some proteins required for cell proliferation. Alternatively, autophagy may protect against tumor initiation and development by favoring cellular differentiation, increasing protein catabolism, or promoting autophagic cell death.
2. Autophagy Promotes Tumor Progression. As tumors enlarge, cancer cells may face metabolic stresses such as nutrient and growth factor deprivation or hypoxia due to insufficient vascularization. In addition, cancer treatments such as radiation, chemotherapy, and so-called target therapies, including those that disrupt angiogenesis inhibit the function of proteasomes or disrupt signaling pathways, can create other forms of cellular stress. Under these circumstances, autophagy may protect the viability of tumor cells by providing nutrients and energy through degradation of cytoplasmic components for the recycling of amino acids and fatty acids. It has been demonstrated that the blunting of autophagy by impeding the early stage of autophagy using 3MA, the inhibiting the formation of autophagolysosomes using hydroxychloroquine (HCQ) or bafilomycin A1, or the silencing of Atg5, Beclin1, Atg10, or Atg12 expression by RNA interference can all facilitate the death of starved cancer cells (Boya et al., 2005) . Autophagy may protect cancer cells against the oxidative stress and DNA damage caused by chemotherapeutic agents by eliminating damaged macromolecules or organelles, allowing the continued survival of cancer cells and thereby contributing to drug resistance. Inhibition of autophagy has been shown to enhance the efficacy of anticancer drugs (Janku et al., 2011) .
Some types of cancer cells, particularly those harboring an activated Ras oncogene, depend on autophagic activity for survival even in the absence of external stressors (Mancias and Kimmelman, 2011) . Both in vitro and in vivo studies have found that expression of oncogenic Ras increased autophagy, which may support transformation and tumor growth through adapting to cellular stresses and maintaining energy levels (Guo et al., 2011; Kim et al., 2011b; Lock et al., 2011; Yang et al., 2011a) . Moreover, after radiotherapy or chemotherapy, constitutive up-regulation of autophagy may favor a dormancy state in residual cancer cells, including cancer stem cells; this may contribute to tumor recurrence and progression White et al., 2010) . Senescence, a state of cell-cycle arrest that may serve as a tumor suppressor, has been suggested as a mechanism underlying tumor dormancy mediated by autophagy (Gewirtz, 2009) . It was demonstrated that autophagy mediates Ras-induced senescence, and that inhibition of autophagy delays senescence in cancer cells (Young et al., 2009) .
3. Future Horizons of Autophagy in Cancer. Autophagy appears to be a double-edged sword in cancer, having both tumor-suppressing and tumorpromoting properties at different stages of cancer. On the one hand, promoting autophagy to prevent persistent tissue damage and chronic inflammation might be beneficial in the setting of cancer prevention; on the other hand, blocking the autophagy-mediated survival of tumor cells is probably advantageous in the treatment of cancer. Thus, modulation of autophagy appears to be a promising but complex new approach to cancer prevention and treatment, although its benefits can be context dependent. Determining how to modulate autophagy as a cancer therapy is an exciting challenge that will provide new insights into cancer biology and approaches to enable cancer eradication.
B. Obesity and Diabetes
Obesity is the phenotypic expression of an imbalance of energy homeostasis. This imbalance is accompanied by the emergence of metabolic and oxidative stress, which may lead to inflammatory responses and organelle dysfunction. Chronic exposure to high energy through nutrient intake increases the demand on synthetic and degradative machinery in tissues such as the liver, adipose tissue, and pancreas, all central of metabolic homeostasis.
Recent studies have shed light on the role of autophagy in the regulation of lipid metabolism and insulin sensitivity. Ineffective handling of macromolecules such as lipids or glycogen could compromise the metabolic function of the liver and blunt the action of insulin . found a down-regulation of autophagy in hepatocytes in both genetic and dietary models of obesity. Suppression of Atg7 expression both in vitro and in vivo results in defective insulin signaling and elevated endoplasmic reticulum stress. By contrast, restoration of Atg7 expression in the liver limited endoplasmic reticulum stress and enhanced the action of insulin and systemic glucose tolerance in the obese mice . These observations indicate that autophagy is an important component of insulin signaling and that Autophagy, Diseases, and Pharmacology reduced autophagy and increased endoplasmic reticulum stress may lead to insulin resistance.
Autophagy has a critical role in normal adipogenesis, and inhibition of autophagy has antiobesity and insulin-sensitizing effects (Goldman et al., 2010) . Mice with Atg7 deletion in the adipose tissues exhibited enhanced insulin sensitivity and higher levels of basal physical activity, and were resistant to obesity while fed a high-fat diet .
Obesity increases the risk of type 2 diabetes. In obesity, the size and number of adipocytes increase, resulting in expansion of adipose tissues. Gain of adipose tissues, in particular visceral adiposity, causes adipocyte dysfunction, which may play a role in the development of insulin resistance and other obesitylinked complications (Lavallard et al., 2012) . Type 2 diabetes is characterized by glucose intolerance, insulin resistance, and relative insulin deficiency Jung et al., 2008) . Atg7 mutant mice show impaired glucose tolerance, inappropriate concentration of circulating insulin, and reduced b-cell mass and pancreatic insulin content. This evidence indicates that autophagy is necessary for maintenance of the structure, mass, and function of pancreatic b cells. It further indicates that impaired autophagy may contribute to insulin deficiency and hyperglycemia, resulting from abnormal turnover and function of cellular organelles (Ebato et al., 2008; Jung et al., 2008) .
C. Cardiovascular Diseases
In the myocardium, autophagy occurs at low levels under normal conditions, and defects in this process will cause cardiac dysfunction and heart failure. Under stressful conditions, autophagy is rapidly increased and plays a protective role to promote cell survival. Excessive autophagy, however, may lead to cell death (Rothermel and Hill, 2008; Gustafsson and Gottlieb, 2009) .
Increasing evidence suggests that defective autophagy is associated with heart disorders, including congestive heart failure, cardiomyopathy, and the Danon disease (Table 1) . Accumulation of autophagosomes was observed in myocardial biopsy samples from patients with the cardiovascular diseases such as coronary artery disease, hypertension, aortic valvular disease, and congestive heart failure (Terman and Brunk, 2005) . It was reported that basal autophagy helps maintain cardiomyocyte function and survival. For example, myocardial-specific deficiency of the autophagy gene Atg5 causes cardiomyopathy in adult mice characterized by hypertrophy and contractile dysfunction (Nakai et al., 2007) . In cultured cardiac myocytes, induction of autophagy reduces the accumulation of misfolded proteins and other intracellular aggregates that are known to contribute to cardiac diseases (Pattison and Robbins, 2011) . Mice with deficiency of LAMP2 show excessive accumulation of autophagic vacuoles and impaired autophagic degradation of long-lived proteins, which may contribute to the incidence of cardiomyopathy (Nishino et al., 2000; Tanaka et al., 2000) .
Apart from its apparent role in maintaining the normal functions of the heart, autophagy is also an adaptive response that protects the heart from various stresses. Activation of autophagy in the stressed heart provides energy substrates and promotes cellular remodeling. It is believed that autophagic activity in cardiac myocytes provides a necessary energy source during the period between birth and suckling (Kuma et al., 2004) . It has been found that autophagy triggered by ischemia is a homeostatic mechanism that reduces apoptosis and the deleterious effects of chronic ischemia (Yan et al., 2005) . Inhibition of autophagy hastens heart failure, accelerates ventricular dysfunction, and increases mortality in mice harboring the aBcrystalin mutant, indicating that autophagy acts as an adaptive response in this proteotoxic model of heart disease (Tannous et al., 2008) .
Autophagy is a protective response to toxic lipopolysaccharides in neonatal rat cardiomyocytes through which damaged organelles are removed (Hickson-Bick et al., 2008) . It has been found that the removal of depolarized mitochondria by mitophagy plays a critical role in protecting the cardiac muscle cells subjected to ischemic stress (Huang et al., 2011) . Cardiac-specific deficiency of the Atg5 gene does not cause any phenotypic abnormalities during the early stages of cardiogenesis under normal conditions, but results in severe cardiac dysfunction after treatment with pressure overload or b-adrenergic stress (Nakai et al., 2007) . Recently, it has been reported that autophagy plays a protective role in HL-1 myocardial cells subjected to ischemia/ reperfusion (I/R), and that inhibition of autophagy renders these cells more sensitive to apoptosis after I/R (Hamacher-Brady et al., 2006) . Consistent with this, it was observed that up-regulation of autophagy induced by I/R constitutes a protective response against BNIP3-mediated apoptotic cell death through removal of damaged mitochondria (Hamacher-Brady et al., 2007) .
There is also the apparently contradictory report that excessive induction of autophagy underlies autophagic cell death and loss of cardiomyocytes (Martinet et al., 2007a) (Table 1) . This hypothesis is supported by reports that dead and dying cardiomyocytes showed the characteristics of autophagy, and that increased autophagy was associated with heart failure (Takemura et al., 2006). Akazawa et al. (2004) provided evidence suggesting that the loss of myocardial cells caused by autophagic cell death plays a causal role in the pathogenesis of heart failure. They observed that degenerated cardiomyocytes of the mouse heart exhibited characteristics indicative of autophagic cell death. Several studies have reported that induction of autophagy contributes to cell death during I/R. Valentim et al. (2006) found that inhibition of autophagy by 1174 knockdown of Beclin1 or treatment with 3-MA enhanced cell survival in the cardiac myocytes treated with I/R. Activation of autophagy in cardiomyocytes may also contribute to heart failure caused by pressure overload (Zhu et al., 2007) , as evidenced by the observation that inhibition of autophagy can diminish pathologic remodeling induced by severe pressure stress. Conversely, increased autophagic activity promotes pathologic remodeling (Zhu et al., 2007) .
In summary, cardiac autophagy appears to function predominantly as a prosurvival mechanism under normal or mildly stressed conditions. When excessive autophagy is present, however, the autophagic machinery may play a self-destructive role, leading to damaged myocardium and congestive heart failure.
D. Neurodegenerative Diseases
The role of autophagy in several neurodegenerative diseases, including Alzheimer disease (AD), Parkinson disease (PD), and Huntington disease (HD) (Rubinsztein et al., 2012) , has received recent attention. Despite the apparently distinct etiologies of these neurodegenerative disorders, pathologically they share the presence of protein inclusions and aggregates within neurons (Rubinsztein, 2006) . Thus, failure of protein degradation may be one cause of the neuronal cell death in these neurodegenerative disorders.
Despite the morphologic evidence of autophagy activity in the neurons from patients with AD, PD, and HD (Levine and Yuan, 2005; Mizushima, 2007) , the role of autophagy in neurodegenerative disorders remains unclear. As in other circumstances we have described, it is not always easy to decipher whether the presence of autophagy is a survival response or a form of programmed cell death. Autophagy is seen in neurons undergoing neurodegeneration, but is this a death response or a failed attempt at survival? These observations suggest a role for autophagy in neurodegeneration. Interventions that block autophagy and increase cell death would suggest a survival role, whereas those that decrease cell death would suggest the opposite. Thus, further experimental and clinical studies that ascertain where autophagy plays a role should be of high priority.
In contrast, there have been studies reporting that accumulation of autophagosomes (indicative of activation of autophagy) acts as a protective mechanism to degrade mutant or toxic proteins. Experiments have shown that reduced autophagic activity could result in disturbance of the degradation of intracellular protein and the formation of the protein aggregates and inclusions that may cause cellular toxicity and disrupt neural function (Hara et al., 2006; Komatsu et al., 2006) . Induction of autophagy can enhance the clearance of cytoplasmic aggregate-prone proteins. Accumulation of ubiquitin aggregates was detected in the central nervous system of mice lacking Atg7 and was accompanied by neurodegeneration, abnormal neurologic signs, and death (Komatsu et al., 2006) . Similarly, mice deficient for Atg5 develop progressive deficits in motor function accompanied by the accumulation of cytoplasmic inclusion bodies in neurons (Hara et al., 2006) . Ambra1, a component of the Beclin1-class III PI3K complex, is a positive regulator of autophagy, and its deficiency in mouse embryos leads to severe neural tube defects associated with uncontrolled cell proliferation (Fimia et al., 2007) .
Following the morphologic evidence of autophagy in neurodegenerative disorders like AD, PD, and HD (Mizushima, 2007) , more studies demonstrated the roles of autophagy in these pathologic conditions. PD, the second most common neurodegenerative disorder, is an age-related disease characterized by resting tremor, slowed movement, postural instability, and muscle rigidity (Janda et al., 2012) . Autophagy has been found to play an important role in the intracellular clearance of a-synuclein (a-syn), a major component of the neuronal cytoplasmic inclusions (Lewy bodies) that characterize PD (Webb et al., 2003) . Overexpression of Beclin1 reduced the accumulation of a-syn and ameliorated the related neuronal pathologic features in a mouse model (Spencer et al., 2009 ). Recent studies have linked mitophagy defects to PD, which is associated with the accumulation of mitochondrial damage. For example, PINK1 and parkin have critical roles in the mitophagic removal of the damaged mitochondria, and mutations in these genes are linked with autosomal recessive PD (Cesari et al., 2003; Vives-Bauza et al., 2010) .
AD is the leading cause of dementia in the aging population, and a close link has been shown between defects of autophagy and AD. It has been observed that expression of Beclin1 was significantly reduced in the brains of patients with AD, and that Beclin1 deficiency not only reduced autophagic activity in neurons but also accelerated b-amyloid accumulation and promoted neurodegeneration. By contrast, up-regulation of Beclin1 decreased amyloid deposition. Thus, restoring autophagy may represent an effective approach to treatment of AD (Pickford et al., 2008) .
HD is a neurodegenerative genetic disorder caused by the expansion of the polyglutamine (polyQ) tract in huntingtin (Htt). This results in the death of striatal medium spiny neurons, with subsequent disruption of both basal ganglia and higher function, eventually leading to the characteristic choreiform movements, cognitive decline, and psychiatric problems. Autophagy is implicated in regulating the turnover of Htt (Sarkar et al., 2007b) , the main component of the nuclear and cytosolic inclusions detected in the HD-affected neurons. Knockdown or knockout of the Atg genes increases the formation of aggregates and toxicity of the polyQ expansion proteins in Caenorhabditis elegans (Jia et al., 2007) . Autophagy, Diseases, and Pharmacology Taken together, autophagy plays a protective role against the neurodegenerative diseases, and defects in autophagy are an important contributor to these disorders. Thus, it can be expected that modulating autophagy activity by a pharmacologic approach or other means might emerge as a novel therapeutic strategy for the neurodegenerative diseases.
E. Aging
The process of aging is closely associated with accumulation of damaged proteins and organelles, in particular, the mitochondria. It has been shown in C. elegans and rodents that decreased generation of damaged proteins and organelles is associated with extension of the life span (Levine and Klionsky, 2004) . Accumulation of damaged proteins and mitochondria may reflect an insufficiency of protein turnover, which may then contribute to the aging process. Autophagy participates in eliminating damaged proteins and organelles, reducing reactive oxygen species (ROS) production, and promoting mitochondrial turnover and biogenesis; all of these may contribute to life-span extension and prevent or delay the development of the complications associated with aging (Rubinsztein et al., 2011) . Normal and pathologic aging are often associated with a reduced autophagic degradation, which may result in an accumulation of protein aggregates and damaged mitochondria, thus contributing to agerelated cellular dysfunctions (Cuervo, 2008) .
In fact, the role of autophagy in increasing life spans has been studied in various model systems such as yeast (Matecic et al., 2010) , C. elegans (Toth et al., 2008) , and fruit flies (Simonsen et al., 2008) . Activation of autophagy has potent antiaging effects, and inhibition of this cellular process accelerates aging and compromises the longevity-promoting effects of caloric restriction (CR) (Rubinsztein et al., 2011) . CR is a key antiaging intervention shown to contribute to extension of life span in diverse eukaryotic organisms including yeast, flies, worms, rodents, and mammals (Colman et al., 2009) , and to be beneficial to human health. CR is a potent inducer of autophagy, and inhibition of autophagy prevents the antiaging effects of CR (Rubinsztein et al., 2011) , suggesting that the effects of CR on longevity are mediated at least in part through activating autophagy. reported that the autophagy genes bec-1 and Ce-atg7 are required for the longevity effects of dietary restriction in C. elegans, providing the first genetic evidence for the role of autophagy in the extension of the life span. Inhibition of mTOR can also extend the life span in several model organisms and confer protection against a variety of age-related pathogeneses; multiple mTORC1-regulated processes, such as mRNA translation and autophagy, likely contribute to the prolongevity effects of mTORC1 inhibition (Johnson et al., 2013) . Evidence from studies in yeast and invertebrates shows that the mTORC1-regulated autophagy is required for the life-span extension caused by dietary restriction or by rapamycin administration (Alvers et al., 2009; Bjedov et al., 2010) . It is believed that there exists a cross-link between the molecular mechanisms regulating autophagy and aging. CR induces autophagy through the activation of Sirt1 and/or the inhibition of mTOR. Signaling pathways involved in stress-resistance and longevity, such as FoxO3 and p53, are also involved in autophagy regulation (Salminen and Kaarniranta, 2009 ).
F. Infectious Diseases
Induction of autophagy may also be beneficial in the treatment of infectious diseases, as this cellular process can defend against microorganisms via selective degradation of pathogens and activation of innate and adaptive immunity (Levine et al., 2011) . It was observed that autophagic activity was increased during host infection by various bacteria and viruses (Rikihisa, 1984; Munz, 2009) . In the C. elegans and Dictyostelium discoideum models, mutations in autophagy genes that diminish autophagy render the hosts more susceptible to infection by invasive bacteria and permit intracellular bacterial replication (Jia et al., 2009 ). Overexpression of Beclin1 can inhibit replication of the Sindbis virus and protect cells against infection, suggesting that autophagy plays a role in host defense against this viral infection (Liang et al., 1998) .
The autophagic machinery is used in the selective delivery of microorganisms to lysosomes in a process called xenophagy . This cellular process can degrade various intracellular and invading pathogens such as bacteria and viruses (Kirkegaard et al., 2004; Nakagawa et al., 2004) . In addition to degrading infectious agents, activation of autophagy enhances antimicrobial innate and adaptive immune signaling (Deretic, 2005) . Autophagy may function as an innate effector against mycobacterial infection through the receptor-dependent or/and receptor-independent pattern-recognition mechanisms (Fabri et al., 2011) . By degrading intracellular pathogens and cytotoxic microbial virulence products, autophagy may support cellular survival during pathogen invasion.
However, induction of autophagy may also aid bacteria and viruses to invade host tissues and escape host defense mechanisms. Bacteria such as Porphyromonas gingivalis and Brucella abortus enter cells and survive within autophagosomal vacuoles. During infection, these bacteria are internalized into the early endosome-like vacuoles and then sequestered into the autophagosomes, thereby inhibiting fusion of autophagosome with lysosome and preventing the degradation by lysosomal hydrolases (Dorn et al., 2002; Marino and Lopez-Otin, 2004 ). Autophagy may also provide pathogens with nutrients for growth, and with substrates for metabolic pathways. Additionally, autophagy is used by 1176 certain types of viruses during replication. For example, Prentice et al. (2004) reported that cellular autophagy was required for replication of the corona virus and mouse hepatitis virus (MHV). Therefore, autophagy can either be favorable or unfavorable to pathogen infection.
Our current knowledge of the role of autophagy in infection suggests that, depending on the type of pathogen, the autophagic machinery can either be used by viruses or bacteria to infect and to grow within host cells, or the autophagic process can function as a protective mechanism against infection. Therefore, as in many other circumstances, autophagy may have both favorable and unfavorable effects. Exploiting autophagy to devise new strategies for treatment of infectious diseases appears to be promising but also challenging, and will largely depend on a more complete understanding of the role of autophagy in different types and stages of infection.
G. Immune Diseases
In addition to degrading pathogens as previously discussed, up-regulation of autophagy may facilitate optimal regulation of innate and adaptive immune signaling (Levine and Deretic, 2007; Kuballa et al., 2012) . Autophagy participates in trafficking events that deliver microbial nucleic acids and antigens to endo/lysosomal compartments for activation of innate immunity (Schmid and Munz, 2007) . The delivery of viral pathogens to Toll-like receptor 7 (TLR7) was impaired and the secretion of both interferon a (IFN-a) and interleukin-12 (IL-12) were decreased in the Atg5 2/2 dendritic cell model (Lee et al., 2007 ). An efficient immune response against pathogens involves complex intracellular antigen-processing events.
It has been found that autophagy may benefit the host by degrading endogenous viral proteins for antigen presentation. For example, during herpes simplex virus 1 (HSV-1) infection, autophagy increases the presentation of endogenous viral antigens to CD8 + T cells on the major histocompatibility complex (MHC) class I molecule (English et al., 2009 ). Autophagy also may enhance presentation of major histocompatibility complex class II to CD4 + T cells and is an important mechanism controlling the homeostasis of CD4 + T cells ). Autophagy appears to be involved in the development and survival of T lymphocytes. For example, Atg5 2/2 CD8 + T lymphocytes display dramatically increased cell death, and Atg5
2/2
CD4
+ and CD8 + T cells fail to undergo efficient proliferation after T-cell receptor stimulation (Pua et al., 2007) .
Not only does the autophagic machinery function in innate and adaptive immunity, but several surface receptors and cytokines involved in innate and adaptive immune responses also stimulate autophagy for the clearance of intracellular pathogens . For instance, Toll-like receptors activate autophagy in response to pathogen invasion (Delgado et al., 2008) . Cytokines of both of innate and adaptive immunity have been reported to regulate autophagy, including IFN-g, TNF-a, IL-4, and IL-13. Among these, IFN-g (Inbal et al., 2002) and TNF-a (DjavaheriMergny et al., 2006) stimulate autophagy, whereas IL-4 and IL-13 block autophagy (Harris et al., 2007) .
Autophagy is also linked to other immune functions such as the secretion of proinflammatory cytokines. Autophagy can mitigate inflammatory reactions through different mechanisms. The rapid removal of apoptotic corpses by autophagy ameliorates tissue inflammation . Autophagy-deficient Atg5
2/2 embryos demonstrate increased inflammation in tissues where there is an impaired clearance of apoptotic cells . Atg16L1-deficient macrophages overproduce the inflammatory cytokines IL-1b and IL-18 after treatment with lipopolysaccharides, suggesting that autophagy is involved in the control of endotoxin-induced inflammatory immune responses (Saitoh et al., 2008) . Autophagy can also inhibit the activation of the NLRP3 "inflammasome" and the secretion of IL-1b and IL-18, likely through improving the quality control of the mitochondria and removing ROS and the cytosolic mitochondrial DNA (Nakahira et al., 2011) . Consistently, it was found that inhibition of mitophagy leads to the accumulation of damaged, ROS-generating mitochondria, and that this is responsible for activating the NLRP3 inflammasome (Zhou et al., 2011) .
Our knowledge of the role of autophagy in immunity has been further strengthened by connections found between the Crohn disease and ATG16L and autophagystimulatory immunity-related GTPase (IRGM), two genes involved in autophagy regulation (Massey and Parkes, 2007; Parkes et al., 2007) . These studies suggest a potential role for the deregulation of autophagy in the pathogenesis of Crohn disease. Genomewide studies have linked several single-nucleotide polymorphisms in the Atg5 gene to susceptibility to systemic lupus erythematosus (SLE), suggesting an involvement of autophagy in this autoimmune disease (Levine et al., 2011) . Another connection between autophagy and chronic inflammation was found in cystic fibrosis, a lifethreatening genetic disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) (Luciani et al., 2010) . A defective cystic fibrosis transmembrane conductance regulator results in deficient autophagy in lung epithelial cells; restoration of autophagy by overexpressing Beclin1 can rescue the disease phenotype.
IV. Pharmacologic Modulation of Autophagy:
Novel Therapeutic Intervention
A. Mechanism of Action of Autophagy Modulators
Understanding the role of autophagy in healthy tissues has helped identify the importance of autophagy in disease. To develop effective autophagy-based Autophagy, Diseases, and Pharmacology therapy, it will be essential to identify the key targets in the autophagy pathway for the development of new therapeutic agents. As discussed earlier, autophagy can play a protective or destructive role in disease states, and thus for therapeutic purposes it would be valuable to identify and develop pharmacologic agents that can induce or inhibit this cellular process. A variety of potentially "druggable" targets affecting autophagy have been identified such as eEF2K, which acts as a positive regulator of autophagy under various stresses, as reported by our laboratory (Wu et al., 2009; Cheng et al., 2011a Cheng et al., , 2013 .
1. Autophagy Inhibitors. Numerous studies have demonstrated that autophagy can be inhibited pharmacologically through targeting the early or late stage of the autophagic process (Fig. 3) . Table 2 lists the compounds identified as inhibitors of autophagy. Like all drugs, the potency, activity, selectivity, and safety as well as other pharmacologic properties such as pharmacokinetics, absorption, distribution, metabolism, and elimination are essential elements for a drug's ultimate clinical utility. The inhibitors that target the early stage of autophagy include 3-MA, wortmannin, and LY294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride], all of which inhibit the class III PI3K (Vps34) and disable the formation of autophagosome. The inhibitors that act on the late stage of autophagy include chloroquine (CQ), bafilomycin A1, leupeptin, and pepstatin. These latter compounds either inhibit the fusion of autophagosomes with lysosomes or the degradation of autolysosomes. The lysosomotropic agents such as CQ and its derivative HCQ can increase lysosomal pH and prevent the digestive activity of hydrolases, leading to inhibition of both the fusion of the autophagosome with the lysosome and the degradative activity of the autolysosomes (Amaravadi et al., 2011) . Bafilomycin A1 is a selective inhibitor of the vacuolar H + ATPase responsible for acidifying lysosomes.
The digestive phase of autophagy can also be blocked by inhibitors of lysosomal proteolysis such as leupeptin and pepstatin. Autophagosomes and lysosomes move along the microtubules to fuse, so microtubule-disrupting agents, including nocodazole, colchicine, and vinblastine, can block the fusion of autophagosomes with lysosomes (Yang et al., 2011c; Rubinsztein et al., 2012) . 2-Phenylethynesulfonamide (PES), a small molecule inhibitor of heat shock protein 70 (HSP70), impairs autophagy (5) The intracellular level of IP3 negatively regulates autophagy via an mTOR-independent mechanism; inhibiting this pathway can induce autophagy. (6) The antiapoptotic proteins Bcl-2 and Bcl-XL can interact with Beclin 1 through the Bcl-2 homology 3 (BH3) domain, thereby inhibiting Beclin1-dependent autophagy; thus, the small molecule mimetics of BH3 can activate autophagy by blocking the interaction between Bcl-2 and Beclin1. (7) Class III PI3K is critical for autophagy initiation, so its inhibitors can suppress autophagy by blocking the formation of autophagosome. (8) Inhibitors of the lysosomal enzymes and lysosomotropic agents that elevate the lysosomal pH can inhibit autophagy through blocking fusion of the autophagosome with the lysosome and degradation of the autolysosome. Autophagy, Diseases, and Pharmacology through its inhibitory effects on lysosomal functions (Leu et al., 2009) . Monensin, an inhibitor of protein transport, inhibits autophagy by preventing the fusion of the autophagosome with the lysosome . Using an imaging-based screen, Liu et al. (2011) recently identified a highly potent small molecule inhibitor of autophagy they named spautin-1 (specific and potent autophagy inhibitor 1), which promotes degradation of the Vps34 complexes via inhibiting ubiquitin-specific processing protease 10 (USP10) and USP13, two ubiquitin-specific peptidases that target the deubiquitination of Beclin1. 2. Autophagy Activators. mTOR, inositol 1,4,5-trisphosphate (IP3), epidermal growth factor receptor (EGFR), Bcl-2, and Bcl-xl negatively regulate autophagy. Thus, drugs targeting these proteins have the capacity to induce autophagy (Fig. 3) . Table 3 lists the compounds that have been identified as activators of autophagy. The mTORC1 inhibitor rapamycin and its analogs temsirolimus (CCI-779), everolimus (RAD-001), and deforolimus (AP-23573) are strong inducers of autophagy (Rubinsztein et al., 2012) inhibitory activity compared with rapamycin (Yu et al., 2010) , but their autophagy-inducing efficacy has not been well documented. By use of an automated cell-based assay, Balgi et al. (2009) found that rottlerin (a potent large-conductance potassium channel opener and an inhibitor of protein kinase C) and three approved drugs, perhexiline (a prophylactic antianginal agent), niclosamide (a teniacide), and amiodarone (an antiarrhythmic agent), activate autophagy by inhibiting mTORC1 signaling. The activity of mTOR is regulated by the class I PI3K-Akt pathway, and negative feedback between the mTORC1 and the PI3K-Akt pathways exists ( (Criollo et al., 2007) .
EGFR is an upstream regulator of the class I PI3K/ Akt pathway known to suppress autophagy through activating mTOR; therefore, induction of autophagy might contribute to the effects of EGFR-targeted therapy. Indeed, cetuximab, a therapeutic antibody that blocks the function of EGFR, induces autophagy in cancer cells (Li and Fan, 2010) . The small molecule mimetics of BH3, (Maiuri et al., 2007a ) and HA14-1 [2-amino-6-bromo-a-cyano-3-(ethoxycarbonyl)-4H-1-benzopy ran-4-acetic acid ethyl ester] (Kessel and Reiners, 2007) , inhibit the interaction between Bcl-2/Bcl-xl and Beclin1 and increase autophagic activity (Fig. 3 and Table 3 ).
Autophagy can also be pharmacologically induced via activating the positive regulators of autophagy. Metformin, a widely used antidiabetic agent, activates AMPK and induces autophagy . In addition, many other drugs activate autophagy through diverse or even unknown mechanisms of action. For example, some cytotoxic agents have been shown to induce autophagy in cancer cells; these agents include TNF-related apoptosisinducing ligand (Han et al., 2008) , histone deacetylase inhibitors vorinostat (SAHA) (Shao et al., 2004) et al., 2009) , panobinostat (Ellis et al., 2009) , and OSU-HDAC42 [or AR42, (S)-(+)-N-hydroxy-4-(3-methyl-2-phenyl-butyrylamino)-benzamide] , and tamoxifen (Bursch et al., 1996) , resveratrol (Scarlatti et al., 2008) , oridonin (Cheng et al., 2009a,b) , temozolomide (Cheng et al., 2012a) , and arsenic trioxide . Other drugs such as the tyrosine kinase inhibitors imatinib (Ertmer et al., 2007) and dasatinib (Milano et al., 2009) , proteasome inhibitors bortezomib and NPI-0052 [(1R,4R,5S)-4-(2-chloroethyl)-1-((S)-((S)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione] (Zhu et al., 2010) , antidepressants fluoxetine and maprotiline (Cloonan and Williams, 2011) , farnesyltransferase inhibitor manumycin A, amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoate], and lonafarnib (Pan et al., 2008) , endoplasmic reticulum stress inducers thapsigargin and tunicamycin , and angiogenesis inhibitors kringle 5 and endostatin (Ramakrishnan et al., 2007) can also induce autophagy, despite their different mechanisms of action (Table 3 ).
B. Application of Autophagy-Based Pharmacotherapy
Recent advances in our understanding of the roles and functions of autophagy in human health and disease provide an exciting opportunity to target autophagy for the treatment of human illnesses (Rubinsztein et al., 2007) . In the following sections, we discuss a few directions that may be of particular use in future investigations.
1. Modulation of Autophagy as a Cancer Therapy. Therapeutic targeting of the autophagy pathway as a new anticancer strategy has been under extensive investigation. Depending on the context, such as tumor type or stage, both of the autophagy-enhancing and autophagy-inhibiting agents may elicit beneficial effects in the treatment of cancer.
a. Use of autophagy inhibitors in cancer treatment. The rationale for inhibiting autophagy for cancer treatment was generated by the observation that increases in autophagy are often observed in cancer cells as an apparent attempt to maintain metabolic homeostasis and to survive external stress such as hypoxia, nutrient deprivation, chemotherapy, or radiotherapy.
Ras-mediated transformation and tumor growth appear to use autophagy to evade metabolic stress and cell death. It was demonstrated that inhibition of autophagy by pharmacologic or genetic means suppressed K-Rasinduced growth of human breast epithelial cells in vitro and tumor growth in animal models (Kim et al., 2011b) . Inhibiting autophagy using CQ or Atg5-targeted smallinterfering RNA (siRNA) inhibited growth and tumorigenicity of pancreatic ductal carcinoma (PDAC, a tumor with K-Ras mutation) cells and in mouse xenograft models . These preclinical results suggest that autophagy might be exploited as a new therapeutic target in the setting of tumors driven by oncogenic Ras, which may lead to further clinical trials using autophagy inhibitors in the patients with Rasdriven tumors. Abnormal autophagic activity was also observed in poorly differentiated non-small-cell lung cancer and was associated with extensive intratumoral Autophagy, Diseases, and Pharmacology 1186 necrosis, which is considered to be a poor prognostic factor (Karpathiou et al., 2011) . Autophagy is up-regulated in tumor cells subjected to various stresses, including chemotherapy and radiotherapy, and blocking autophagy may increase the effectiveness of concomitant treatments (Townsend et al., 2012) , such as inhibition of autophagy by CQ-sensitized human cancer cells subjected to hypoxia and human xenografts subjected to radiation therapy (Rouschop et al., 2010) . It has been shown that inhibiting autophagy enhanced the efficacy of chemotherapy and targeted therapy against cancer, and the increased efficacy was associated with increased tumor cell deaths. Suppression of autophagy via knockdown of autophagy genes or use of chemical inhibitors of autophagy such as 3-MA, CQ, or HCQ can sensitize tumor cells to the effects of chemotherapeutic drugs (Rubinsztein et al., 2012) , tamoxifen (Amaravadi et al., 2007) , TNF-a (Giampietri et al., 2012) , proteasome inhibitors Zhu et al., 2010) , glycolytic inhibitor 2-deoxy-D-glucose (2-DG) (Wu et al., Choi and Lee, 2011) , tyrosine kinase inhibitors (Gupta et al., 2010) , histone deacetylase (HDAC) inhibitors (Shao et al., 2004; Carew et al., 2007) , and EGFR antibody and inhibitors Li and Fan, 2010) . We recently reported that blunting of autophagy by inhibiting eEF2K significantly increases the antitumor effects of Akt inhibitors such as MK-2206 [8-[4-(1-aminocyclobutyl) phenyl]-9-phenyl-1,2,4-triazolo[3,4-f ][1,6]naphthyridin-3(2H)-one dihydrochloride] (Cheng et al., 2011a,b) . We also found that combinatorial treatment of MK-2206 with the small molecule inhibitor of EGFR tyrosine kinase gefitinib promotes a switch from autophagy to apoptosis and enhances the efficacy of gefitinib against human glioma (Cheng et al., 2012b) . The dual inhibitors of PI3K/mTOR signaling can activate cytoprotective autophagy, and inhibitors of autophagy can cooperate with the PI3K/mTOR dual inhibitors to promote tumor cell death . The sensitizing effects of inhibiting autophagy on the antitumor efficacy of chemotherapeutic agents have been recapitulated in preclinical models of Myc-induced lymphoma (Amaravadi et al., 2007) , colon cancer Carew et al., 2010; , prostate cancer , and glioma .
On the basis of the preclinical data demonstrating that targeting autophagic survival can reinforce the efficacy of anticancer therapy, a number of clinical trials have been launched to test whether the inhibitors of autophagy can benefit cancer patients (Table 4) .
Of the known autophagy inhibitors, thus far only CQ and HCQ have been actively evaluated in clinical trials, partly because the pharmacologic and toxicologic profiles of these two drugs are well documented. CQ was originally introduced as a therapeutic agent for treating malaria in 1947, and it is still used as an effective and safe antimalarial drug. Furthermore, CQ is used for the treatment of rheumatoid arthritis, systemic lupus erythematosus, amoebic hepatitis, and other connective tissue disorders (Solomon and Lee, 2009) . Because of retinal toxicity, a major side effect of CQ, HCQ was later developed through modification of the structure of CQ by introducing a hydroxyl group at the end of the side chain, a structural modification that results in a decreased ability to cross the blood-retinal barrier and reduces the retinal toxicity (Townsend et al., 2012) . The more favorable safety profile makes HCQ preferable to CQ (Ruiz-Irastorza et al., 2010) .
Early results with CQ in cancer treatment have been reported. Patients with glioblastoma were treated with surgery, chemotherapy, or radiotherapy with or without CQ (Sotelo et al., 2006) . The median survival in the CQ arm was 24 months compared with 11 months in the controls (Sotelo et al., 2006) . There are also several ongoing phase I/II trials evaluating the combination of HCQ or CQ with chemotherapeutic agents in patients with multiple myeloma, brain, lung, breast, colorectal, pancreas, kidney, or prostate cancers (Table 4) . These results will be informative and hold the potential for increasing the interest in this field.
b. Use of autophagy activators in cancer treatment. As discussed earlier, evidence suggests that increased autophagy can kill cells. However, the weakness of many studies has been that the demonstration of autophagy after a cytotoxic treatment does not prove that autophagy contributed to cell death, only that it was associated with it. It is equally plausible that increased autophagy in these settings was a failed attempt at cell survival. To more definitively demonstrate a cytotoxic role for autophagy, inhibition would have to increase survival. In fact, most studies do not demonstrate a causative role for autophagy in promotion of cell death. Nonetheless, induction of autophagic cell death has been suggested as a potential strategy to eradicate tumor cells. In fact, several anticancer drugs have been reported to trigger cell death through autophagymediated mechanisms (Levy and Thorburn, 2011) .
Rapamycin, a selective mTOR inhibitor, induces autophagy (Takeuchi et al., 2005) , as does temsirolimus, another inhibitor of mTOR whose autophagy-inducing effect has been attributed to its antitumor mechanism in mantle cell lymphoma (Yazbeck et al., 2008) . Likewise, the inhibitory effect of the mTOR inhibitor everolimus on lymphoblastic leukemia was associated with activation of autophagy (Crazzolara et al., 2009 ). The ATP-competitive inhibitors of mTORC1/mTORC2, WYE-125132 (WYE-132) (Yu et al., 2010) , and AZD8055 (Chresta et al., 2010) have demonstrable anticancer activity against several solid tumors both in vitro and in vivo; AZD8055 is currently in phase I clinical trials. The tyrosine kinase inhibitor dasatinib has been reported to enhance the antiglioma effect of temozolomide through triggering autophagic cell death, and this action can be antagonized by the autophagy inhibitor 3-MA (Milano et al., 2009) . Akt inhibitors induce a greater autophagic response and cause more cell death when combined with radiotherapy or chemotherapy (Fujiwara et al., 2007) than when used alone.
Other types of drugs possessing an autophagyinducing effect have also found their potential application in cancer treatment. For instance, autophagic cell death may contribute to the anticancer actions of the histone deacetylase (HDAC) inhibitor vorinostat (SAHA) (Shao et al., 2004; Liu et al., 2010) , the estrogen receptor antagonist tamoxifen (Bursch et al., 1996) , and the antidepressants fluoxetine and maprotiline (Cloonan and Williams, 2011) , as inhibition of autophagy decreases the efficacy of these agents against tumor cells. The cytotoxicity of tumor necrosis factor a (TNF-a) in fibrosarcoma cells is also associated with activation of autophagy (Cheng et al., 2008) . The natural products arsenic trioxide , resveratrol (Opipari et al., 2004) , and saponin (Ellington et al., 2005) induce autophagic cell death in malignant glioma, ovarian cancer, and colon cancer, respectively. Thus, it is 1188 conceivable that some autophagy-inducing agents may also be useful in cancer therapies because of their ability to trigger autophagic cell death. The same attention given to inhibitors of autophagy should be given to autophagy-inducing or autophagy-enhancing agents.
2. Therapeutic Effects of Autophagy Modulators on Cardiovascular Diseases. Increasing evidence has linked autophagy with the normal function of cardiomyocytes and with the pathogenesis of multiple forms of heart disease, suggesting that components of the (Table 5) . So far, nine patents have disclosed the use of autophagy activators and inhibitors in the treatment of cardiovascular diseases (Nemchenko et al., 2011) . Cardiac autophagy is often activated in response to stress, and enhances the clearance of misfolded and other harmful proteins. Rapamycin, a potent activator of autophagy, has been reported to prevent cardiac hypertrophy caused by thyroid hormone or by aortic banding, and represses existing hypertrophy that results from pressure overload (Shioi et al., 2003; McMullen et al., 2004; Nishida et al., 2009 ). Sulfaphenazole (SUL), an antimicrobial agent, can protect the heart against I/R injury reportedly through inducing autophagy . Likewise, chloramphenicol succinate has been shown to activate autophagy and reduce myocardial damage during I/R (Sala-Mercado et al., 2010) .
Macrophages can degrade extracellular matrix and promote the death of smooth muscle cells, thereby playing a role in atherogenesis. The clearance of macrophages from atherosclerotic plaques through autophagy has been suggested as an attractive therapeutic strategy for atherosclerosis (Martinet et al., 2007b) . In line with these findings, the stent-based delivery of everolimus was shown to selectively clear macrophages from atherosclerotic plaques in rabbits by activating autophagy without altering smooth muscle cells (Verheye et al., 2007) .
In other situations such as the presence of severe pressure overload, suppressing rather than activating autophagy might be beneficial. For instance, trichostatin A, an inhibitor of histone deacetylases, blunts autophagy and inhibits pathologic cardiac remodeling during severe pressure overload (Cao et al., 2011) . Propofol, an antioxidant agent widely used as an anasthetic, has also been shown to inhibit autophagic cell death and limit myocardial damage during I/R injury in rats (Noh et al., 2010) . Granulocyte colony- stimulating   TABLE 5 Preclinical studies of the effects of autophagy modulators on various diseases factor (G-CSF) can improve the survival, cardiac function, and remodeling in the UM-X7.1 hamster model of dilated cardiomyopathy; such beneficial effects appear to be associated with a reduction in autophagic cell death . Also, the reduction of autophagy in cardiac myocytes after I/R has been associated with increased cell survival (Valentim et al., 2006) .
Autophagy plays a protective role in cardiomyocytes exposed to diverse forms of pathologic insults. Nutrient deprivation is the most effective inducer of autophagy in mammalian cells (Mizushima, 2007) . Intermittent fasting can protect the heart from ischemic injury and attenuates cardiac remodeling after myocardial infarction, likely through the induction of autophagy; however, prolonged starvation may trigger severe cardiovascular complications and cardiac death (Martinet et al., 2007a) . Thus, selection of activators or inhibitors of autophagy for prevention or treatment of cardiovascular diseases will be complicated. To date, there have been no clinical data reporting the efficacy of pharmacologic modulation of autophagy in cardiac diseases. However, it is likely that some drugs already in clinical use may have stimulatory or inhibitory effects on autophagy and these "tool" compounds may elucidate a path forward in this area.
3. Use of Autophagy Modulators for Neurologic Disorders. Several neurodegenerative diseases are characterized by accumulation of intracellular aggregateprone proteins, including the polyQ-expanded Htt in HD, a-syn in PD, and amyloid-b in AD. Autophagy plays a critical role in degrading these misfolded and aggregate proteins. Thus, activating autophagy to facilitate the degradation of toxic proteins is a potentially novel approach to treatment of neurodegenerative disorders (Table 5) .
Experiments have already shown that activation of autophagy enhances the clearance of the mutant Htt and protects against neurodegeneration in a fly model of HD (Sarkar et al., 2007b) . The autophagy inducer rapamycin has been reported to promote autophagic clearance and reduce the toxicity of various polyQ proteins, including mutant Htt (Ravikumar et al., 2002; Berger et al., 2006) . In the fly and mouse models of HD, rapamycin induces autophagy and protects against Htt-induced neurodegeneration (Ravikumar et al., 2004) . The rapamycin analog CCI-779 decreases the formation of aggregates and lessens the symptoms of HD in a mouse model of this disease (Ravikumar et al., 2004) . Rapamycin can also increase the clearance of a-syn in cells (Webb et al., 2003) .
Lithium (Sarkar et al., 2005) and trehalose (Sarkar et al., 2007a) promote the clearance of both mutant Htt and a-syn via autophagic degradation through an mTOR-independent pathway. Rapamycin in combination with lithium showed a greater protection against neurodegeneration in an HD fly model as compared with either drug alone (Sarkar et al., 2008) . Inhibition of nitric oxide generation by N G -nitro-L-arginine methyl ester can induce autophagy, enhance the degradation of mutant Htt, and alleviate toxicity of harmful proteins in several models of HD (Sarkar et al., 2011) . Combinatory use of trehalose and rapamycin has showed an additive effect on the clearance of toxic proteins and increased autophagic activity (Sarkar et al., 2007a) .
These results point to the potential role of autophagy activators in the treatment of neurodegenerative diseases. To date, there are very few reported clinical results demonstrating that modulation of autophagy indeed represents an effective therapeutic intervention for these devastating diseases.
4. Autophagy Modulators for Treatment of Other Diseases.
a. Infectious and immune diseases. As described earlier, autophagy has been implicated in the host defenses against infectious agents. Therefore, it would be intriguing to determine whether targeting autophagy can serve as an effective therapeutic strategy against infectious diseases.
Several drugs that protect against microbial infections also induce autophagy (Table 5) (Chiu et al., 2009b) and Salmonella enterica serovar Typhimurium in murine macrophages in vitro and in vivo (Chiu et al., 2009a) . Also, 1a,25-dihydroxycholecalciferol (1,25D3), the most active form of vitamin D, inhibited replication of human immunodeficiency virus (HIV) in human macrophages, and this was also associated with enhanced autophagy (Campbell and Spector, 2012) . In host cells infected with Mycobacterium tuberculosis, induction of autophagy is correlated with the activity of antimycobacterial chemotherapy (Kim et al., 2012) .
These results raise the possibility that some drugs already in clinical use for the treatment of infectious diseases exert their anti-infection effects, at least partially, via inducing autophagy. However, most of the data have resulted from in vitro and animal studies, and it is unclear whether those findings can be translated into the clinical treatment of certain infections.
Tat-beclin1, a recently developed autophagy-inducing peptide, has been shown to have potential therapeutic efficacy in the treatment of several infectious diseases (Shoji-Kawata et al., 2013) . Tat-beclin1 peptide, derived from a region of beclin1, can bind human immunodeficiency virus 1 (HIV-1) and interact with a newly identified negative regulator of autophagy GAPR-1 (Golgi-associated plant pathogenesis-related protein 1, also known as GLIPR2). This study demonstrated that this autophagy-inducing peptide decreased the accumulation of polyglutamine expansion protein aggregates Autophagy, Diseases, and Pharmacology and the replication of several pathogens as well as reduced mortality in mice infected with chikungunya or West Nile virus (Shoji-Kawata et al., 2013) . It would be intriguing to observe the effectiveness of this autophagyinducing peptide agent in clinical trials.
b. Aging. Aging is characterized by alterations in the disposal of damaged proteins and organelles such as mitochondria, suggesting a role for autophagy in this process (Donati, 2006) . Accordingly, it has been shown that genetic disruption of TOR can extend the life span of C. elegans (Vellai et al., 2003) . Similar observations were made in Drosophila (Kapahi et al., 2004) . Pharmacologic inhibition of mTOR by methionine sulfoximine or rapamycin increases the life span in Saccharomyces cerevisiae (Powers et al., 2006) . Resveratrol, a polyphenol compound, has been shown to promote longevity in several model organisms, and Sirt1-mediated autophagy is required for the life-span prolonging effects of this agent (Morselli et al., 2010) . Activation of autophagy is also crucial the longevitypromoting effects of spermidine, a cationic polyamine that triggers autophagy through inhibiting histone acetyltransferases and activating various autophagyrelated transcripts (Eisenberg et al., 2009) . Thus, it is likely that activating autophagy may represent a new strategy for interventions in aging and that modulators of autophagy could be among the class of future antiaging agents.
V. Conclusion and Perspective
Our goal has been to provide a perspective on how autophagy-based pharmacotherapy may provide a new arena for impacting human disease. The relevant molecular mechanisms involved in autophagy regulation and their impact on numerous pathologic conditions have yielded startling, sometimes contradictory new insights. Together, the many basic, preclinical, and clinical studies suggest to us that there will be a role for modulators of autophagy in the treatment of the human illnesses. Indeed, the targeting of autophagy as a therapeutic strategy for various diseases already has begun to be explored and has shown promise.
In particular, pharmacologic approaches to the modulation of autophagy have elicited great interest. Rational searching for, designing, screening, and testing of inhibitors and activators of autophagy have become an exciting, active area within drug discovery and development, with the expectation that correcting autophagy will be a new and useful approach to the treatment of illnesses. Several drugs that affect autophagy have already been tested in animal models and in clinical trials for diseases such as cancer and cardiovascular disorders, and there are early indications of promise. Nevertheless, despite the promise of autophagy modulators as pharmacotherapeutic agents, a number of problems remain that need to be resolved before clinical modulation of autophagy in various diseases can progress. Some of these problems include the following.
1. Although we have learned a great deal about autophagy at the molecular, biochemical, and cellular levels, the precise role of autophagy in individual diseases remains incompletely understood. Many studies have been limited, showing only an association between the presence of autophagy and the effect of drugs rather than implicating autophagy directly. Future studies need to be more rigorously designed to distinguish the precise role of autophagy in disease states and in the responses to treatment. To date, translating preclinical observations into the clinic has progressed most rapidly in oncology, but major opportunities for progress exist in several other therapeutic areas, including cardiology, neuroscience, and infectious diseases and autoimmunity. 2. It is likely that in each of those disease areas there will be segments of the population more likely to respond than others, thereby requiring the identification of predictive pharmacodynamics and surrogate end-point biomarkers. 3. Most of the current drugs described as modulators of autophagy do not directly or specifically regulate the autophagy process but rather act on the pathways involved in activating or inhibiting this cellular process, which raises the question of specificity. Development of selective inhibitors or activators that act directly on the regulatory targets will rely largely on the identification and further understanding of the key targets that control autophagy and the elucidation of the molecular structure of the targets. In addition, as our sophistication in the discovery of autophagyspecific ligands increases, it may be possible to use concepts now extant in other areas of pharmacology and discover functionally selective autophagy modulators that have an appropriate signaling bias that maximizes therapeutic effects and minimizes side effects. 4. To facilitate the discovery and development of the autophagy-targeted drugs, sensitive, effective, reliable, and accurate high-throughput screening (HTS) assays would need to be established and chemical libraries enriched for new scaffolds. 5. As the modulators of autophagy (either inhibitors or activators) are expected to be administered in combination with other therapeutic agents, the possible drug-drug interactions, pharmacokinetic or pharmacodynamic, might present a potential problem that should be considered in designing and developing autophagy-targeted drugs and therapeutic regimens.
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In conclusion, with the growing interest in cellular autophagy among the biomedical community, we hope that we have provided a uniquely pharmacologic point of view of the opportunities and potential applications of autophagy-targeted pharmacologic agents for therapeutic intervention in various human diseases. As a variety of human disorders have been found to be associated with changes in the activity of autophagy, this important cellular process is now considered a viable target for drug discovery, and pharmacologic modulation of autophagy as a remedy provides an unusual opportunity for exploration. Based on what we have discussed, we have reason to believe that, like the apoptosis-targeted drugs that have already shown some degree of success in clinical settings, new therapeutic agents that modulate autophagy will soon emerge and come into clinical application for the benefit of human health and that autophagy-based pharmacotherapy will become a new subject in pharmacology.
